Version May 2024
| Drug | Receptor activity | Predominant clinical effects | |||
| Alpha-1 | Beta-1 | Beta-2 | Dopaminergic | ||
| Phenylephrine | +++ | 0 | 0 | 0 | SVR ↑↑, CO ↔/↓ |
| Norepinephrine | +++ | ++ | 0 | 0 | SVR ↑↑, CO ↔/↑ |
| Epinephrine | +++ | +++ | ++ | 0 | CO ↑↑, SVR ↓ (low dose) SVR/↑ (higher dose) |
| Dopamine (mcg/kg/min)* | |||||
| 0.5 to 2 | 0 | + | 0 | ++ | CO |
| 5 to 10 | + | ++ | 0 | ++ | CO ↑, SVR ↑ |
| 10 to 20 | ++ | ++ | 0 | ++ | SVR ↑↑ |
| Dobutamine | 0/+ | +++ | ++ | 0 | CO ↑, SVR ↓ |
| Isoproterenol | 0 | +++ | +++ | 0 | CO ↑, SVR ↓ |
+++: very strong effect; ++: moderate effect; +: weak effect; 0: no effect; SVR: systemic vascular resistance; CO: cardiac output.
* Doses between 2 and 5 mcg/kg/min have variable effects.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
